<DOC>
<DOCNO>EP-0629627</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3155	A61K3154	A61K31554	A61P4300	A61K31553	A61K315375	C07C31750	A61K31535	A61K31542	A61K3800	C07C31914	A61K31542	A61P900	C07D49800	A61K3154	C07C32700	C07C31700	C07C32359	A61P912	A61K3155	C07K500	C07D51304	C07C31920	A61K315365	A61K315365	A61P904	C07C32300	A61K315383	C07D49804	C07K5078	A61K31535	C07D51300	A61K31553	C07C31900	A61K3800	A61K31554	A61P4300	C07C32734	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61P	A61K	A61K	C07C	A61K	A61K	A61K	C07C	A61K	A61P	C07D	A61K	C07C	C07C	C07C	A61P	A61K	C07K	C07D	C07C	A61K	A61K	A61P	C07C	A61K	C07D	C07K	A61K	C07D	A61K	C07C	A61K	A61K	A61P	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61P43	A61K31	A61K31	C07C317	A61K31	A61K31	A61K38	C07C319	A61K31	A61P9	C07D498	A61K31	C07C327	C07C317	C07C323	A61P9	A61K31	C07K5	C07D513	C07C319	A61K31	A61K31	A61P9	C07C323	A61K31	C07D498	C07K5	A61K31	C07D513	A61K31	C07C319	A61K38	A61K31	A61P43	C07C327	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of the formula 

wherein X is O or S-(O)
t
 ; n is one or two ; m is zero or one ; Y is CH₂, 
O, or S-(O)
t
 provided that Y is O or S-(O)
t
 only when m is one ; and A is 

are dual inhibitors of NEP and ACE. Compounds wherein A is  
are selective ACE inhibitors. Also disclosed are methods of preparation 
and intermediates. 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
This invention is directed to novel compounds
containing a fused bicyclic ring which are useful as
angiotensin converting enzyme inhibitors. Some of
these compounds also possess neutral endopeptidase
inhibitory activity. This invention is also directed
to pharmaceutical compositions containing such
selective or dual action inhibitors and the method of
using such compositions. This invention is also
directed to the process for preparing such novel
compounds, novel intermediates, and processes for
preparing such intermediates.The novel fused bicyclic inhibitors of this
invention include those compounds of the formula

and pharmaceutically acceptable salts thereof
wherein:
A is
X is O or S-(O)t;R1 and R12 are independently selected from
hydrogen, alkyl, alkenyl, cycloalkyl, substituted
alkyl, substituted alkenyl, aryl, substituted aryl,
heteroaryl, cycloalkyl-alkylene-, aryl-alkylene-,
substituted aryl-alkylene-, and heteroaryl-alkylene-
or R1 and R12 taken together with the carbon to which
they are attached complete a cycloalkyl ring or a
benzofused cycloalkyl ring;R2 is hydrogen, or
R3, and R7 are independently selected from
hydrogen, alkyl, substituted alkyl, aryl-(CH2)p-,
substituted aryl-(CH2)p-; R6 is alkyl, substituted alkyl, cycloalkyl-(CH2)p-,
aryl-(CH2)p-, substituted aryl-(CH2)p-, or
heteroaryl-(CH2)p-;m is zero or one;Y is CH2, S-(O)t or O provided that Y is
S-(O)t or O only when m is one;n is one or two;p is zero or an integer from 1 to 6;q is zero or an integer from 1 to 3;r is zero or one; andt is zero, one, or two.The term "alkyl" refers to straight or
branched chain radicals having up to seven carbon
atoms. The term "substituted alkyl" refers to such
straight or branched chain radicals of 1 to 7 carbons
wherein one or more, preferably one, two, or three,
hydrogens have been replaced by a hydroxy, amino,
cyano. halo, trifluoromethyl, -NH(C1-4 alkyl),
-N(C1-4 alkyl)2, C1-4 alkoxy, C1-4 alkylthio, or
carboxy.The term "cycloalkyl" refers to saturated
rings of 3 to 7 carbon atoms with cyclopropyl,
cyclobutyl, cyclopentyl, and cyclohexyl being most
preferred.The term "alkenyl" refers to straight or
branched chain radicals of 3 to 7 carbon atoms having
one or two double bonds. Preferred "alkenyl" groups
are straight chain radicals of 3 to 5 carbons having
one double bond.The term "substituted alkenyl" refers to such
straight or branched radicals of 3 to 7 carbons
having one or two double bonds wherein a hydrogen has
been replaced by a hydroxy, amino, halo,
trifluoromethyl, cyano, -NH(C1-4

</DESCRIPTION>
<CLAIMS>
A compound of the formula


or such a compound in pharmaceutically acceptable salt
form,wherein:


A is


or

X is O or S-(O)
t
;
R
1
 and R
12
 are independently selected from the
group consisting of hydrogen, alkyl, alkenyl,

cycloalkyl, substituted alkyl, substituted alkenyl,
aryl, substituted aryl, heteroaryl, cycloalkyl-alkylene-,

aryl-alkylene-, substituted aryl-alkylene-, 
and heteroaryl-alkylene- or R
1
 and R
12

taken together with the carbon to which they are
attached complete a cycloalkyl ring or a benzofused

cycloalkyl ring;
R
2
 is hydrogen or

R
3
 and R
7
 are independently selected from
the group consisting of hydrogen, alkyl, substituted

alkyl, aryl-(CH
2
)
p
-, substituted aryl-(CH
2
)
p
-
R
6
 is alkyl, substituted alkyl, cycloalkyl-(CH
2
)
p
-,
aryl-(CH
2
)
p
-, substituted aryl-(CH
2
)
p
-, or
heteroaryl-(CH
2
)
p
-; 
m is zero or one;
Y is CH
2
, S-(O)
t
 or O provided that Y is
S-(O)
t
 or O only when m is one;
n is one or two;
p is zero or an integer from 1 to 6;
q is zero or an integer from 1 to 3;
r is zero or one; and
t is zero, one, or two;
the term "alkyl" refers to straight or
branched chain radicals having up to seven carbon

atoms,
the term "substituted alkyl" refers to such
straight or branched chain radicals of 1 to 7 carbons

wherein one or more
hydrogens have been replaced by a hydroxy, amino,

cyano, halo, trifluoromethyl, -NH(C
1-4
 alkyl),
-N(C
1-4
 alkyl)
2
, C
1-4
 alkoxy, C
1-4
 alkylthio, or
carboxy;
the term "cycloalkyl" refers to saturated
rings of 3 to 7 carbon atoms;
the term "alkenyl" refers to straight or
branched chain radicals of 3 to 7 carbon atoms having

one or two double bonds; 
the term "substituted alkenyl" refers to such
straight or branched radicals of 3 to 7 carbons

having one or two double bonds wherein a hydrogen has
been replaced by a hydroxy, amino, halo,

trifluoromethyl, cyano, -NH(C
1-4
 alkyl),
-N(C
1-4
 alkyl)
2
, C
1-4
 alkoxy, C
1-4
 alkylthio, or
carboxy;
the term "alkylene" refers to straight or
branched chain radicals having up to seven carbon

atoms, i.e. -CH
2
-, -(CH
2
)
2
-, -(CH
2
)
3
-, -(CH
2
)
4
-.

the term "aryl" refers to phenyl, 1-naphthyl,
and 2-naphthyl; the term "substituted aryl" refers

to phenyl, 1-naphthyl, and 2-naphthyl having a
substituent selected from C
1-4
 alkyl, C
1-4
 alkoxy,
C
1-4
 alkylthio, halo, hydroxy, trifluoromethyl,
amino, -NH(C
1-4
 alkyl), or -N(C
1-4
 alkyl)
2
, and di-
and tri-substituted phenyl, 1-naphthyl, or 2-naphthyl

wherein said substituents are selected from methyl,
methoxy, methylthio, halo, hydroxy, and amino;
the term "heteroaryl" refers to unsaturated
rings of 5 or 6 atoms containing one or two O and S

atoms and/or one to four N atoms provided that the
total number of hetero atoms in the ring is 4 or

less, the heteroaryl ring being attached by way of an
available carbon or nitrogen atom;
the term "heteroaryl" further including bicyclic
rings wherein the five or six membered ring

containing O, S, and N atoms as defined above is
fused to a benzene or pyridyl ring, and wherein 

said mono or bicyclic heteroaryl ring
can also be additionally substituted at an available

carbon atom by a C
1-4
 alkyl, halo, hydroxy, benzyl, .
or cyclohexylmethyl, or if the mono or bicyclic

ring has an available N-atom such N atom can also be
substituted by an N-protecting group such as



2,4-dinitrophenyl, C
1-4
 alkyl, benzyl, or
benzhydryl.
A compound of Claim 1 having the formula



wherein:

A is

R
2
 is hydrogen or

R
3
 is hydrogen or C
1-4
 alkyl;
r is zero or one; 
R
1
 is aryl-CH
2
-, substituted aryl-CH
2
-,
heteroaryl-CH
2
-, cycloalkyl-CH
2
- wherein cycloalkyl
is of 3 to 7 carbons, or straight or branched chain

alkyl of 1 to 7 carbons and R
12
 is hydrogen; or
R
1
 and R
12
 taken together with the carbon to which
they are attached complete a cycloalkyl ring of 5 to

7 carbons;
R
6
 is C
1-4
 alkyl or phenyl;
n is one or two;
m is zero or one;
X is O or S; and
Y is CH
2
, O, or S provided that Y is O or S
only when m is one.
A compound of Claim 2 wherein:

R
2
 is hydrogen or

R
3
 is hydrogen;
r is zero or one;
R
1
 is benzyl, cyclopropylmethyl, or straight
or branched chain alkyl of 3 to 5 carbons;
R
12
 is hydrogen;
n is one or two;
m is zero or one;
X is O or S; and
Y is CH
2
, O, or S provided that Y is O or S
only when m is one.
A compound of Claim 3 wherein:

X is S:
Y is CH
2
;
n is two;
m is one;
r is zero or one;
R
2
 is hydrogen; 
R
1
 is benzyl or isobutyl; and
R
12
 is hydrogen; or
X is S;
Y is CH
2
;
n is one;
m is one;
r is zero;
R
2
 is hydrogen;
R
1
 is benzyl; and
R
12
 is hydrogen; or
X is S;
Y is CH
2
;
n is two;
m is zero;
r is zero;
R
2
 is hydrogen;
R
1
 is benzyl, cyclopropylmethyl, n-butyl,
isobutyl, n-propyl, or -CH
2
O(CH
3
)
3
, and
R
12
 is hydrogen; or
X is O;
Y is CH
2
;
n is two;
m is one;
r is zero;
R
2
 is hydrogen;
R
1
 is benzyl; and
R
12
 is hydrogen; or
X is O;
Y is CH
2
;
n is two;
m is zero;
r is zero;
R
2
 is hydrogen;
R
1
 is benzyl; and 
R
12
 is hydrogen; or
X is O;
Y is O;
n is two;
m is one;
r is zero;
R
2
 is hydrogen;
R
1
 is benzyl; and
R
12
 is hydrogen; or
X is S;
Y is O;
n is two;
m is one;
r is zero;
R
2
 is hydrogen;
R
1
 is benzyl; and
R
12
 is hydrogen.
The compound of Claim 4:

[4S-[4α(R*),7α,10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxo-7H-pyrido[2,1-b][1,3]
thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,10aβ]]-octahydro-4-[(2 mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxo-7H-pyrido[2,1-b][1,3]
-thiazepine-7-carboxylic
acid, 1,1-dimethylethylamine

salt;
[4S-[4α(S*),7α,10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxo-7H-pyrido[2,1-b][1,3]
-thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,10aβ]]-octahydro-4-[[2-[mercaptomethyl)-1-oxo-3-phenylpropyl)amino]
-5-oxo-7H-pyrido-[2,1-b][1,3]
thiazepine-7-carboxylic
acid; 
[4S-[4α(R*), 7α, 10aβ]]-octahydro-4-[(2-mercapto-4-methyl-1-oxo-pentyl)amino]
-5-oxo-7H-pyrido[2,1-b][1,3]
thiazepine-7-carboxylic
acid;
[3R-[3α(S*),6α,9aβ]]-hexahydro-3-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-4-oxo-2H,6H-pyrido[2,1-b]-[1,3]
thiazine-6-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxopyrrolo[2,1-b][1,3]
-thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(3-cyclopropyl-2-mercapto-1-oxopropyl)amino]
-3-oxopyrrolo-[2,1-b][1,3]
thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(2-mercapto-1-oxohexyl)amino]
-5-oxopyrrolo[2,1-b][1,3]
-thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(2-mercapto-1-oxo-4-methylpentyl)amino]
-5-oxopyrrolo[2,1-b][1,3]
-thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(2-mercapto-1-oxopentyl)amino]
-5-oxopyrrolo[2,1-b][1,3]
-thiazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(2-mercapto-4,4-dimethyl-1-oxopentyl)amino]
-5-oxopyrrolo[2,1-b]-[1,3]
thiazepine-7-carboxylic
acid: 
[4S-[4α(R*),7α,10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxo-7H-pyrido[2,1-b][1,3]
oxazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,9aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxopyrrolo[2,1-b][1,3]
oxazepine-7-carboxylic
acid;
[4S-[4α(R*),7α,10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxo[1,4]oxazino[3,4-b]
[1,3]-oxazepine-7-carboxylic

acid; or
[4S-[4α(R*),7α,10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]
-5-oxo[1,4]oxazino[3,4-b]
[1,3]-thiazepine-7-carboxylic

acid.
The compound according to claim 1 having the formula


or such a compound in pharmaceutically acceptable salt form.
A pharmaceutical composition for use in the
treatment of cardiovascular disease such as

hypertension and congestive heart failure comprising
a pharmaceutically acceptable carrier and one or more

compounds of the formula 


or such a compound in pharmaceutically acceptable salt form,
wherein A, X, Y, n, m and R
3
 are as defined in
Claim 1.
A compound of the formula



or such a compound in salt form wherein:

X is O or S;
n is one or two;
m is zero or one; provided that when X, n and Y
are simultaneously 0, 1 and CH
2
 respectively, m is one;
Y is CH
2
, 0, or S provided that Y is 0 or S
only when m is one;
R
3
 is hydrogen, C
1-4
 alkyl, or aryl-(CH
2
)p-;
and
p is zero or an integer from 1 to 6.
A process for preparing the compounds as
defined in claim 1 having the formula



which comprises:

a) when A is


and R
3
 is hydrogen, coupling the acylmercapto
sidechain of the formula



or an activated form thereof with the amine of the
formula



in the presence of a coupling reagent wherein X, Y,
m, n, R
6
, r, R
1
,and R
12
 are as defined in Claim 1 and
R
3
 is hydrogen or an acid protecting group followed 
by removal of the acyl group



and the R
3

acid protecting group; and,
b) when A is


coupling the carboxylic acid of the formula


or an activated form thereof with the amine of the
formula



in the presence of a coupling reagent wherein X, Y,
m, n, R
1
 and R
12
 are as defined in Claim 1, and R
3

and R
7
 are acid protecting groups.
A process for preparing the compounds of
the formula



wherein:

X is O or S;
n is one or two;
m is zero or one;
provided that when X, n and y are simultaneously O, 1 and CH
2

respectively, m is one;
Y is CH
2
, O or S provided that Y is O or S
only when m is one; and
R
3
 is an acid protecting group;

which comprises;

(a) coupling an amino acid of the formula


with the amino acid ester of the formula 


to give the dipeptide


wherein:

P
1
 is an amino protecting group or a group
which together with the N-atom forms a protecting

group; and
P
2
 is a hydroxy or mercapto protecting group;
(b) selectively removing the P
2
 protecting
group from the product of part (a);
(c) cyclizing the product of part (h) to give 


and
(d) removing the P
1
 protecting group of the
product of part (c) to give the desired product.
A process of Claim 10 wherein:

X is S;
n is one or two;
Y is CH
2
;
m is zero or one;

which comprises:

(a) coupling an amino acid of the formula


with the amino acid ester of the formula


to give the dipeptide of the formula 


wherein:

P
1
 is an amino protecting group or a group
which together with the N-atom forms a protecting

group; and
P
2
 is a hydroxy protecting group;
(b) selectively removing the P
2
 protecting
group from the product of part (a) to give the

corresponding hydroxy compound;
(c) converting the hydroxy produce from part
(b) to the mercaptan of the formula


(d) cyclizing the mercaptan product of part
(c) to give 



and
(e) removing the P
1
 protecting group from the
product of part (d) to give the desired product.
A process of Claim 10 wherein:

X is S;
n is two,
Y is S or O; and
m is one;

which comprises;

(a) coupling an amino acid of the formula


with the amino acid ester of the formula


to give the dipeptide of the formula 


wherein:

P
1
 is an amino protecting group or a group
which together with the N-atom forms a protecting

group; and
P
2
 is a hydroxy protecting group;
(b) selectively removing the P
2
 protecting
group from the product of part (a) to give the

corresponding hydroxy compound;
(c) converting the hydroxy product from part
(b) to the mercaptan of the formula


(d) cyclizing the mercaptan product of part
(c) to give 



and
(e) removing the P
1
 protecting group from the
product of part (d) to give the desired product.
A process for preparing the compounds of
the formula



wherein:

X is O or S;
n is one or two;
m is zero or one; and
R
3
 is an acid protecting group;

which comprises:

(a) coupling an amino acid of the formula


with the hydroxy amino acid ester of the formula 


to give the dipeptide of che formula


wherein:

P
1
 is an amino protecting group or a group
which together with the N-atom forms a protecting

group; and
P
2
 is a hydroxy or mercapto protecting group;
(b) oxidizing the hydroxy product ot part (a)
to the aldehyde of the formula


(c) selectively removing the P
2
 protecting
group from the aldehyde product of part (b);
(d) cyclizing the product of part (c) to give


and
(e) removing the P
1
 protecting group of the
product of part (d) to give the desired product.
A compound of any one of claims 1-6 for use
as an active pharmaceutical substance.
Use of a compound of any one of claims 1-6
for the manufacture of a medicament for treatment of

cardiovascular disease.
</CLAIMS>
</TEXT>
</DOC>
